Prelude Therapeutics Incorporated (PRLD) Tuesday said it has entered into partnership with Merck to evaluate Prelude's PRT3789 combined with Merck's KEYTRUDA in Phase 2 study in patients with SMARCA4-mutated cancers.
As per the agreement, Merck will provide KEYTRUDA to Prelude, the sponsor of the Phase 2 combination study. Prelude and Merck retain all commercial rights to their respective compounds, including as monotherapy or as combination therapies.
PRT3789, a potent and highly selective, first-in-class SMARCA2 degrader, is currently in Phase 1 study in biomarker selected SMARCA4 mutant patients.
For comments and feedback: editorial@rttnews.com